Details for New Drug Application (NDA): 208159
✉ Email this page to a colleague
The generic ingredient in VISTOGARD is uridine triacetate. There are thirty-six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the uridine triacetate profile page.
Summary for 208159
Tradename: | VISTOGARD |
Applicant: | Btg Intl |
Ingredient: | uridine triacetate |
Patents: | 1 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 208159
Generic Entry Date for 208159*:
Constraining patent/regulatory exclusivity:
Dosage:
GRANULE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for NDA: 208159
Ingredient-type | Analogs/Derivatives Pyrimidines |
Suppliers and Packaging for NDA: 208159
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
VISTOGARD | uridine triacetate | GRANULE;ORAL | 208159 | NDA | BTG International Inc | 50633-220 | 50633-220-04 | 4 PACKET in 1 CARTON (50633-220-04) / 10 g in 1 PACKET (50633-220-10) |
VISTOGARD | uridine triacetate | GRANULE;ORAL | 208159 | NDA | BTG International Inc | 50633-220 | 50633-220-20 | 20 PACKET in 1 CARTON (50633-220-20) / 10 g in 1 PACKET (50633-220-10) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | GRANULE;ORAL | Strength | 10GM/PACKET | ||||
Approval Date: | Dec 11, 2015 | TE: | RLD: | Yes | |||||
Patent: | ⤷ Sign Up | Patent Expiration: | Aug 17, 2027 | Product Flag? | Substance Flag? | Delist Request? | |||
Patented Use: | EMERGENCY TREATMENT OF ADULT & PEDIATRIC PATIENTS FOLLOWING FLUOROURACIL OR CAPECITABINE OVERDOSE,OR WHO EXHIBIT EARLY-ONSET,SEVERE OR LIFE-THREATENING CARDIAC OR CNS TOXICITY OR UNUSUALLY SEVERE ADVERSE REACTIONS WITHIN 96 HOURS |
Expired US Patents for NDA 208159
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Btg Intl | VISTOGARD | uridine triacetate | GRANULE;ORAL | 208159-001 | Dec 11, 2015 | ⤷ Sign Up | ⤷ Sign Up |
Btg Intl | VISTOGARD | uridine triacetate | GRANULE;ORAL | 208159-001 | Dec 11, 2015 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription